

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (Original) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism, characterized in that it comprises pilocarpine combined with at least one bioadhesive polymer so as to allow dissolution and local attachment to the tissues of the buccopharyngeal cavity.

2. (Original) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein the pilocarpine is the basic pilocarpine or pilocarpine in the form of salt, chlorohydrate or nitrate.

3. (Original) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it is combined with a mass substrate of the family of soluble carbohydrates with a low molecular weight, glucose or lactose.

4. (Currently Amended) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1, [[ 2 or 3,]] wherein it comprises at least a buffer.

5. (Currently Amended) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1 ~~any of the preceding claims~~, wherein it comprises at least one lubricant.

6. (Currently Amended) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1 ~~any of the preceding claims~~, wherein it comprises at least one softening agent.

7. (Currently Amended) Pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1 ~~any of the preceding claims~~, wherein it comprises at least one hydrophilic substance.

8. (Currently Amended) Galenical formulation that includes a composition according to claim 1 ~~any of claims 1 to 7~~, wherein it makes it possible with the pilocarpine:

- to directly and instantaneously access the muscarine-like receptors of the submucous glandular structures,
- to protect it and to keep it stable with regard to the light, the temperature and the oxidation,
- to allow it to dissolve and to be attached locally to tissues of the buccopharyngeal cavity.

9. (Currently Amended) Sublingual tablet for the treatment of hypoptyalism, having the composition according to claim 1 any of the preceding claims 1 to 7, wherein it comprises at least the pilocarpine and at least one bioadhesive polymer.

10. (Original) Sublingual tablet for the treatment of hypoptyalism according to claim 9, wherein the bioadhesive polymer is selected from among the family of cellulose derivatives, gums or polymers of the alginic acid type and derivatives, carboxy-vinyl polymer, carbomer, macrogols, gelatin, povidone, or pectins.

11. (Currently Amended) Sublingual tablet for the treatment of hypothyroidism according to claim 9 [[or 10]], wherein it has the following formula:

- pilocarpine that is basic or in salt form:

2.5 mg

- magnesium stearate:

10.0 mg

- sodium or disodium hydrogen phosphate:

90.0 mg

- K 100 methocel:

50.0 mg

- 6 000 polyethylene glycol:

40.0 mg

- hyaluronic acid:

20.0 mg

- lysozyme chlorhydrate:

15.0 mg

- compressed sorbitol qsp for 1000 mg:

772.5 mg

12. (Original) Sublingual tablet for the treatment of hypothyroidism according to claim 11, wherein the sodium or disodium hydrogen phosphate is replaced by sodium carbonate or sodium bicarbonate in the same proportions.

13. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 2, wherein it comprises at least a buffer.

14. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 3, wherein it comprises at least a buffer.

15. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 2, wherein it comprises at least one lubricant.

16. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 3, wherein it comprises at least one lubricant.

17. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 2, wherein it comprises at least one softening agent.

18. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 3, wherein it comprises at least one softening agent.

19. (New) Pharmaceutical composition that is useful as a medicine for the treatment of hypothyroidism according to claim 2, wherein it comprises at least one hydrophilic substance.

20. (New) Sublingual tablet for the treatment of hypothyroidism according to claim 10, wherein it has the following formula:

- pilocarpine that is basic or in salt form:

2.5 mg

- magnesium stearate:

10.0 mg

- sodium or disodium hydrogen phosphate:

90.0 mg

- K 100 methocel:

50.0 mg

- 6 000 polyethylene glycol:

40.0 mg

- hyaluronic acid:

20.0 mg

- lysozyme chlorohydrate:

15.0 mg

- compressed sorbitol qsp for 1000 mg:

772.5 mg